GlobeNewswire Clinical StudiesOriginal article
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Completes Patient Enrollment in Phase II Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors
Phase 2positiveOpamtistomigPositive
AI Analysis
Summary
Leads Biolabs announced completion of patient enrollment (70 patients) in its Phase II study of Opamtistomig for first-line advanced biliary tract cancer, demonstrating favorable safety and robust efficacy that exceeded expectations. The study entered expansion phase in April 2026 based on positive interim results.
Clinical Trial Data
Phase
Phase II
Primary Endpoint
Met
Patients
70
Outcome Details
Phase II study completed enrollment of 70 patients with favorable safety profile and robust efficacy exceeding expectations; expansion phase entered in April 2026
Importance:7/10
Sentiment:
0.85
PD-L1 inhibitor4-1BB bispecific antibodybiliary tract cancerimmune-cold tumorspatient enrollment completedexpansion phase
Read the original article
Published by GlobeNewswire Clinical Studies on July 30, 2026 10:36 AM